21 August 2006
© Informa UK Ltd 2002-2006
| rimonabant | |
| ||
Synonyms: | Zimulti, Acomplia, SR-141716, SR-141716A | |
| ||
Originator and Phase: | Sanofi-Aventis | Registered |
| ||
Therapy Group: | Alimentary Tract and Metabolic Products (A) | |
| ||
Therapies: | Anorectic/Antiobesity (A8A3) | |
| Dependence treatment (N9A) | ||
| Antidiabetic (A10B) | ||
| Hypolipaemic/Antiatherosclerosis (C10) | ||
Pharmacology: | Cannabinoid CB1 antagonist | |
|
| |
| Indication(s) and Phase(s): | Obesity | Registered |
| Addiction, nicotine | Phase III | |
| Addiction, alcohol | Phase III | |
| Diabetes, Type II | Phase III | |
| Hyperlipidaemia, general | Phase III | |
| Atherosclerosis | Phase III | |
Predicted Launch Years | Mean | Mode | Median |
| 2007 Q2 | 2006 Q3 | 2006 Q4 |
| |||
Development History | |||
| Preclinical | 1994 | ||
| Phase I | 1996 | ||
| Phase II | 1997 | ||
| Phase III | 2001 | ||
| Pre-registration | 2005 | ||
| Registered | 2006 | ||
| Launched | |||
| Probability of Successful Launch (%) | ||||
| Therapy | Therapy Group | Company | All Drugs | |
| From Preclinical to Launch | 3 | 11 | 12 | 10 | |
| From Phase I to Launch | 18 | 40 | 47 | 41 | |
| From Phase II to Launch | 32 | 51 | 58 | 53 | |
| From Phase III to Launch | 86 | 74 | 82 | 76 | |
| From Pre-registration to Launch | 86 | 87 | 90 | 89 | |
| From Registered to Launch | 86 | 93 | 95 | 94 | |
| Withdrawn after Launch | 17 | 4 | 4 | 3 | |
| Total number of active drugs | 87 | 440 | 119 | 6830 | |
Year | Worldwide Sales ($ US millions) |
2006 | 69 |
2007 | 431 |
2008 | 831 |
Peak Sales | 4327 |
21 August 2006 | © Informa UK Ltd 2002-2006 |
| |
21 August 2006 | © Informa UK Ltd 2002-2006 |